TY - JOUR AU - Metro, Giulio AU - Di Maio, Massimo PY - 2018 TI - Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? JF - Translational Lung Cancer Research; Vol 7, Supplement 3 (September 26, 2018): Translational Lung Cancer Research 1 Y2 - 2018 KW - N2 - Targeted treatment with a tyrosine kinase inhibitor (TKI) is associated with high response rates and significantly prolonged progression-free survival in the minority of patients (approximately 15–20%) with advanced non-small cell lung cancer (NSCLC) whose tumor harbors an epidermal growth factor receptor ( EGFR ) mutation, anaplastic lymphoma kinase ( ALK ) rearrangement or ROS1 rearrangement (1). UR - https://tlcr.amegroups.org/article/view/23047